Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.69 |
| ▸ | MAPT | P10636 | 7/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.69 |
| ▸ | NR2F2 | P24468 | 2/20 | 0.69 |
| ▸ | HTT | P42858 | 2/20 | 0.69 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.69 |
| ▸ | LMNA | P02545 | 3/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | NPC1 | O15118 | 6/20 | 0.52 |
| ▸ | RAB9A | P51151 | 6/20 | 0.52 |
| ▸ | MEN1 | O00255 | 5/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | ABL1 | P00519 | 4/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3610538 | 0.83 | ALDH1A1 (0.54) | ALDH1A1MAPTSMN1; SMN2NR2F2HTT | |
| SCHEMBL3604832 | 0.81 | MAPT (0.78) | ALDH1A1MAPTSMN1; SMN2NR2F2HTT | |
| SCHEMBL3604493 | 0.81 | NPC1 (0.54) | ALDH1A1MAPTSMN1; SMN2NR2F2HTT | |
| SCHEMBL3608764 | 0.81 | ALDH1A1 (0.61) | ALDH1A1MAPTSMN1; SMN2NR2F2HTT | |
| SCHEMBL17456987 | 0.80 | MAPT (1.00) | ALDH1A1MAPTSMN1; SMN2NR2F2HTT | |
| SCHEMBL29839931 | 0.80 | MAPT (1.00) | ALDH1A1MAPTSMN1; SMN2NR2F2HTT | |
| SCHEMBL27768288 | 0.79 | ALDH1A1 (0.46) | ALDH1A1MAPTSMN1; SMN2NR2F2HTT | |
| SCHEMBL3609848 | 0.74 | RAB9A (0.59) | ALDH1A1MAPTSMN1; SMN2LMNANPC1 | |
| SCHEMBL3607158 | 0.72 | RAB9A (0.75) | ALDH1A1MAPTSMN1; SMN2HTTNPSR1 | |
| SCHEMBL3603474 | 0.72 | RAB9A (0.71) | ALDH1A1MAPTSMN1; SMN2LMNANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298340-A1 | Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies | ASTRAZENECA AB (SE) | 2010-11-25 | — | — | US | claimed |
| US-20100298340-A1 | Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies | ASTRAZENECA AB (SE) | 2010-11-25 | — | — | US | disclosed |
| US-20100063043-A1 | SUBSTITUTED 2-OXO-3-PHENYL-5-CARBONYLAMINOMETHYL-1, 3-OXAZOLINES AND THEIR USE AS ANTICOAGULANT AND ANTITHROMBOTICS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-03-11 | — | — | US | disclosed |
| US-7582666-B2 | Substituted 2-oxo-3-phenyl-5-carbonylaminomethyl-1,3-oxazolines and their use as anticoagulant and antithrombotics | BAYER SCHERING PHARMA AG (DE) | 2009-09-01 | — | — | US | disclosed |
| US-20060173047-A1 | Substituted 2-oxo-3-phenyl-5-carbonylaminomethyl-1, 3-oxazolines and their use as anticoagulant and antithrombotics | BAYER AKTIENGESELLSCHAFT (DE) | 2006-08-03 | — | — | US | disclosed |
| US-7034017-B2 | Substituted oxazolidinones and their use in the field of blood coagulation | BAYER AKTIENGESELLSCHAFT (DE) | 2006-04-25 | — | — | US | disclosed |
| US-20050080081-A1 | Substituted oxazolidinones and their use in the field of blood coagulation | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060173047-A1 | Substituted 2-oxo-3-phenyl-5-carbonylaminomethyl-1, 3-oxazolines and their use as anticoagulant and antithrombotics | F2, SERPINC1, PROC | ALDH1A1 130/4885MAPT 4861/4885SMN1; SMN2 2917/4885 |
| US-20100298340-A1 | Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies | GRN, MAPT, GUCY1B1 | ALDH1A1 1302/4885MAPT 2/4885SMN1; SMN2 96/4885 |
| US-20050080081-A1 | Substituted oxazolidinones and their use in the field of blood coagulation | F2, F11, F12 | ALDH1A1 247/4885MAPT 4680/4885SMN1; SMN2 3089/4885 |
| US-20100063043-A1 | SUBSTITUTED 2-OXO-3-PHENYL-5-CARBONYLAMINOMETHYL-1, 3-OXAZOLINES AND THEIR USE AS ANTICOAGULANT AND ANTITHROMBOTICS | F2, SERPINC1, PROC | ALDH1A1 130/4885MAPT 4861/4885SMN1; SMN2 2917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.